CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.
Breakdown
- FDA approves Wegovy for treatment of MASH, a serious liver disease. 21s
- MASH affects about 5% of people in the U.S. and one in three overweight or obese individuals globally. 29s
- Analysts project the new indication could add nearly $2 billion in peak sales for Novo Nordisk. 49s
- Wegovy and Ozempic will both be available for $4.99 a month for out-of-pocket payers. 1m 14s
- Both drugs have the same active ingredient but are marketed for different conditions. 1m 31s